Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mobic · 2 trials · 1 indication
Bioequivalence based on Cmax
Bioequivalence based on AUC0-inf
Bioequivalence based on AUC0-t
| Arm | Type | Description |
|---|---|---|
| Meloxicam | EXPERIMENTAL | Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period |
| Mobic® | ACTIVE_COMPARATOR | Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period |
| Name | Type | Description |
|---|---|---|
| Meloxicam 15 mg Tablets | DRUG | 1 x 15 mg, single-dose fasting |
| Mobic® 15 mg Tablets | DRUG | 1 x 15 mg, single-dose fasting |
Inclusion Criteria: * Non-smoking male or female with a minimum age of 18 years (i.e. non-smoker or non tobacco user for at least 90 days prior to pre-study medical). * Body mass Index (BMI = weight/height²) greater than or equal to 18.5 kg/m² and less than or equal to 29.9 kg/m². * Availability of...
Mobic is a small molecule drug being developed by Teva Pharmaceutical Industries Limited. It is currently in Phase 1 clinical trials for healthy volunteers. The drug is being studied under fasting and non-fasting conditions to evaluate its pharmacokinetics.
Mobic is developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials for this small molecule drug.
Mobic is in Phase 1 clinical development. It has completed two Phase 1 trials, both involving healthy volunteers. The drug is investigational and has not been approved for any indication.
Mobic has two completed Phase 1 trials: NCT00840476, which studied Meloxicam 15 mg tablets under fasting conditions, and NCT00840879, which studied the same tablets under non-fasting conditions. Both trials enrolled 28 healthy participants each in Canada.
Mobic is the brand name for meloxicam, a small molecule drug. The clinical trials for Mobic specifically test meloxicam 15 mg tablets. Teva Pharmaceutical Industries Limited is developing this drug.